演題抄録

FACO International Workshop

開催概要
開催回
第53回・2015年・京都
 

Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthetase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1

演題番号 : FWS4-3

[筆頭演者]
Kuramochi Hidekazu:1,2 
[共同演者]
Okano Yusuke:3、Nakajima Go:2、Katagiri Satoshi:1,3、Ariizumi Shunichi:3、Hayashi Kazuhiko:2,3、Araida Tatsuo:1、Yamamoto Masakazu:3

1:Dept of Gastrointestinal Surgery, Yachiyo Medical Center, Tokyo Women's Medical University、2:Dept. of Chemotherapy and Palliative Care, Tokyo Women's Medical University、3:Dept of Gastrointestinal Surgery, Tokyo Women's Medical University

 

Background : Several case reports show a dramatic response of hepatocellular carcinoma (HCC) to therapy using S-1. Thymidylate synthetase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) mediate 5-fluorouracil metabolism are associated with the response of tumors to fluoropyrimidines. The aim of this study was to investigate the association between the levels of TYMS and DPYD mRNAs and the efficacy of S-1 for treating patients with HCC.
Methods : We studied 35 patients with HCC who received S-1 upon recurrence (S-1 group) and 20 patients who never received a fluoropyrimidine derivative (control group). The levels of TYMS and DPYD mRNA in surgically resected formalin-fixed paraffin-embedded specimens were determined using real-time reverse transcription-polymerase chain reaction assays.
Results : Overall survival (OS) of S-1 group patients with high levels of DPYD mRNA was significantly longer than compared with that of patients with low levels (median 501 days vs 225 days, P = 0.016). Similarly, the OS of those patients with high levels of TYMS mRNA was significantly longer compared with those with low levels (median 503 days vs 239 days, P = 0.0076). In contrast, there was no significant difference in OS of the control group between patients with high and low levels of DPYD and TYMS mRNAs. The levels of TYMS and DPYD mRNAs did not correlate with the patients' clinicopathological characteristics.
Conclusions : The levels of TYMS and DPYD mRNAs may serve as predictive markers for patients with HCC who receive S-1 chemotherapy.

キーワード

臓器別:肝臓

前へ戻る